Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butylphthalide plus edaravone dexborneol versus either monotherapy after thrombectomy for acute ischemic stroke
ChiCTR2500100650Phase 4Completed
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ischemic stroke comparing Butylphthalide monotherapy, Edaravone dexborneol monotherapy and Butylphthalide + edaravone dexborneol (3 arms). Primary endpoints: modified Rankin Scale score at day 90 and hepatorenal function at day 90. Started Apr 2025; status: completed.
02
Drugs
butylphthalideedaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500100650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100650.